Isis Innovation analysed the project entitled “Zinmed Vietnam JSC” originating from LIF Fellow, Chu Duc Hoang from Zinmed, Vietnam in terms of its long, medium and short-term commercialisation potential. The invention is a treatment management application for diabetics. It provides news and automatic healthcare tracking tools via a smartphone and wearable device and includes appointment management service linked to doctors, clinics and hospitals

1. Isis Innovation, Ltd. P a g e | 1 CONFIDENTIAL
Further Supporting Materials for Commercialisation Strategy
Isis Innovation analysed the project entitled “Zinmed Vietnam JSC” originating
from LIF Fellow, Chu Duc Hoang from Zinmed, Vietnam in terms of its long,
medium and short-term commercialisation potential. The invention is a
treatment management application for diabetics. It provides news and automatic
healthcare tracking tools via a smartphone and wearable device and includes
appointment management service linked to doctors, clinics and hospitals.
This note is the supporting materials pack to assist the Fellow in her
commercialisation strategy.
I. Information requested by the Fellow
Chu Duc Hoang and his team would like to receive information on the potential
global market, which he would like to target for the commercialisation of her
technology. In particular, the Fellow wished to identify the potential customers,
the countries where the market is most active and the way to derive a successful
sales strategy. The patents for the invention have entered the PCT stage and the
territories selected for protection were the US, Germany, Japan, India and
China.
This note covers:
1. Strategic marketing support; and
2. A list of companies (potential partners/B2B users)
II. Strategic Marketing Support
This technology is targeted towards countries that see poor diabetes education,
poor diabetic control and poor access to specialist diabetes clinicians, e.g.
Vietnam. However, whilst the software might benefit from copyright protection
the overall package of support could be replicated by a competitor. IE suggests
that it could be a better way to commercialise the product by collaborating and
partnering with a major player in the field, preferable, a large international
company.
Such an organisation could be manufacturers of insulin (e.g. Eli Lilly) or
manufacturers of glucose testing equipment (e.g. Sanofi). IE provides a few lists
of companies in each sector and suggests that the Fellow approaches the
companies in all groups and gathers the feedback from the industry on which
group is most appropriate for the given technology and which sector, which
generate the most interest.

2. Isis Innovation, Ltd. P a g e | 2 CONFIDENTIAL
The best way to gauge the interest from the industry sector is to carry out the
primary research. IE suggests that the Fellow creates a small 1-page technology
profile, where the technology description, its capabilities and advantages are
clearly outlined and provide the information on the IP held and the data
supporting the efficacy of the technology. The next step would be to contact
each company identified as a potential partner in tern and market the
technology to the potential partner company as a licensing opportunity.
The information gathered would enable the Fellow to develop a clear
understanding of the market niche and the customer requirements in his field
and prepare the pack of documents necessary for the next step which could be
the licensing agreement if the industry feedback is positive or the R&D strategy
if the feedback was negative.
However, it must be noted that the large international player would be able to
sell the product outside Vietnam; and it would be advisable for the company to
licence the technology to the international player for commercial exploitation
abroad.
Other organisations, potentially interested in the given technology include
government organisations, global insurance and re-insurance companies and,
particularly, the large companies operating in the growing field of wellness and
population health management.
To market the technology to international markets it would be necessary 1) to
provide multiple language capability and support and 2) to demonstrate that the
cost of treating diabetic complications could be reduced by the use of the
technology.
III. Potential partners/manufacturers
Manufacturers of insulin: Piramal Healthcare, Novo Nordisk India Pvt. Ltd,
Sanofi Aventis, Abbott India Ltd, Torrent Pharmaceuticals Ltd, USV Ltd, Nicolas
Piramal India Ltd, Cadila Pharmaceuticals Ltd, Eli Lilly and Company (India) Pvt.
Ltd, Cardiovascular (Ranbaxy Laboratories Ltd), Biocon (India) Ltd, Aventis
Pharma Ltd, Shreya Life Sciences Pvt. Ltd, Wockhardt Ltd., Sarabhai Piramal
Pharmaceutical
Manufacturers of glucose testing equipment: 77 Elektronika Kft., Abbott
Diabetes Care, Inc., Accruex Biomedical Pvt. Ltd, Acon Laboratories, Inc.,
AgaMatrix, Inc., AiMedics Pty Ltd, A. Menarini Diagnostics S.r.l., Apex,
Biotechnology Corp., Arkray, Inc., Aventir Biotech, LLC, Bayer HealthCare LLC,
Diabetes Care, Bionime Corporation, Biopeak Corporation, BodyTel Europe
GmbH, Calisto Medical, Inc., Cyber Medical Ltd., Cybiocare, DexCom, Inc.,
Diagnostic Devices, Inc., DIRAmed LLC, Echo Therapeutics, Inc., Eumed Biotech

3. Isis Innovation, Ltd. P a g e | 3 CONFIDENTIAL
Co., Ltd., Eyesense GmbH, F. Hoffmann-La Roche AG, Fora Care Inc., Freedom
Meditech, Inc., GlucoCom, GlucoLight Corporation, Glucoplus Inc., GlySens
Incorporated, Grove Instruments Inc., HealthPia USA, Home Diagnostics, Inc.,
IN4 Technology Corporation, InLight Solutions, Inc., Integrity Applications Ltd.,
Intuity Medical, Inc., i-SENS, Inc., Lein Applied Diagnostics Ltd., LifeScan, Inc.,
LighTouch Medical, Inc., Luminous Medical, Inc., Medtronic Diabetes, National
Diagnostic Products Pty. Limited, Nova Biomedical Corporation, OrSense Ltd.,
Panasonic Shikoku Electronics Co., Ltd., PreciSense A/S, Sensors for Medicine
and Science, Inc., Sensys Medical, Simple Diagnostics, Solianis Monitoring AG,
Standard Diagnostics, Inc., Teco Diagnostics, Tyson Bioresearch, Inc., US
Diagnostics, Inc., VeraLight, Inc., Visual Pathways Inc., VivoMedical, Inc.,
Ypsomed AG
Smaller players in the field and examples of their products could be found here:
http://www.medicalexpo.com/medical-manufacturer/blood-glucose-meter-
607.html
Insurance companies: United Healthcare, Kaiser Permanente, Aetna, Humana,
Signa, Bupa, Aviva Health Insurance, AXA PPP Health Insurance, Blue Cross,
Blue Shield, Allianz, Wellpoint Inc. Group, Centene Corp, HIP Insurance, HCSC
Group, Highmark Group, Ping An,
Re-insurance companies, providing health insurance and re-insurance:
Munich Re, Swiss Re, Hannover Re, SCOR, ParterRe, General Insurance
Corporation of India, China Reinsurance Corp., RGA Re
Wellness/Population Health Management companies: Discovery Vitality,
Cerner, OptumHealth, McKesson Corporation, Verisk Health Inc., Health Catalyst
LLC, WellCentive, Inc., Almeda, Conifer Health Solutions, LLC, IBM Corporation,
i2i Systems, Inc., Healthagen, LLC, WebMD.